A case of pathological complete response to lt. Lateral lymph node metastasis from lower rectal cancer by S-1 combined neoadjuvant chemoradiotherapy

Shunichi Kimura, Shinobu Ohnuma, Hideaki Karasawa, Takeshi Aoki, Katsuyoshi Kudoh, Kazuhiro Watanabe, Naoki Tanaka, Munenori Nagao, Tomoya Abe, Hiroaki Musha, Takanori Morikawa, Fuyuhiko Motoi, Yu Katayose, Takeshi Naitoh, Michiaki Unno

Research output: Contribution to journalArticlepeer-review

Abstract

A 54-year-old man presented with an enlarged left (lt) lateral lymph node (LLN), which was detected by magnetic resonance imaging (MRI) and positron emission tomography/computed tomography (PET-CT). Endoscopic examination of the colon revealed the presence of a type 1 tumor, 20mm in diameter, in the lower rectum; the tumor was diagnosed as a well-differentiated adenocarcinoma (tub1). The patient received combined neoadjuvant chemoradiotherapy (nCRT)with S- 1 for treatment of the rectal cancer and LLN metastasis (MP, T2N3M0, Stage IIIb). S-1 was administered orally at a dose of 120 mg/day on days 1-14, and 22-35; a total dose of 45 Gy was delivered (1.8 Gy/day, for 25 days). Upon nCRT, there was a remarkable reduction in the tumor size, the primary tumor receded, and the LLN decreased from 16 mm to 8 mm in diameter. The maximum standardized uptake value (SUVmax) also decreased from 3.8 to 1.9 on PET-CT. Six weeks after nCRT, ultralow anterior resection and bilateral lymph node dissections were performed. Histopathological examination showed a partial presence of cancer cells in the scarred primary tumor; however, no viable cancer cells were observed in the lt. LLN.

Original languageEnglish
Pages (from-to)1560-1562
Number of pages3
JournalGan to kagaku ryoho. Cancer & chemotherapy
Volume41
Issue number12
Publication statusPublished - 2014 Nov 1

ASJC Scopus subject areas

  • Medicine(all)

Fingerprint Dive into the research topics of 'A case of pathological complete response to lt. Lateral lymph node metastasis from lower rectal cancer by S-1 combined neoadjuvant chemoradiotherapy'. Together they form a unique fingerprint.

Cite this